Additional file 1 of How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
Drummond, M., Ciani, O., Fornaro, G., Jommi, C., Dietrich, E. S., Espin, J., Mossman, J. & de Pouvourville, G.
(2024).
Additional file 1 of How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
[Dataset]. figshare.
https://doi.org/10.6084/m9.figshare.26589306
Additional file 1.
| Item Type | Dataset |
|---|---|
| Publisher | figshare |
| DOI | 10.6084/m9.figshare.26589306 |
| Date made available | 13 August 2024 |
| Keywords | cost-effectiveness analysis, advanced therapy medicinal products, health technology assessment, managed entry agreements, reimbursement, medicine, infectious diseases, sociology, pharmacology, biotechnology, Biological Sciences |
| Resource language | Other |
| Departments | LSE |
Explore Further
- Drummond, M., Ciani, O., Fornaro, G., Jommi, C., Dietrich, E. S., Espin, J., Mossman, J. & de Pouvourville, G. (2023). How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? BMC Health Services Research, 23(1). https://doi.org/10.1186/s12913-023-09494-5 (Repository Output)
Available at: 10.6084/m9.figshare.26589306
Access level: Open
Licence: Creative Commons: Attribution 4.0
Downloads